263 related articles for article (PubMed ID: 21422819)
21. [Listeria monocytogenes: a dangerous pathogen used as a vector for the new generation of vaccines].
Tkachuk MV; Iarovinskiĭ FO; Tonevitskiĭ AG
Vopr Med Khim; 2000; 46(3):256-64. PubMed ID: 11033885
[TBL] [Abstract][Full Text] [Related]
22. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16.
Gunn GR; Zubair A; Peters C; Pan ZK; Wu TC; Paterson Y
J Immunol; 2001 Dec; 167(11):6471-9. PubMed ID: 11714814
[TBL] [Abstract][Full Text] [Related]
23. Regression of established tumors in mice mediated by the oral administration of a recombinant Listeria monocytogenes vaccine.
Pan ZK; Ikonomidis G; Pardoll D; Paterson Y
Cancer Res; 1995 Nov; 55(21):4776-9. PubMed ID: 7585503
[TBL] [Abstract][Full Text] [Related]
24. In vivo bactofection: listeria can function as a DNA-cancer vaccine.
Souders NC; Verch T; Paterson Y
DNA Cell Biol; 2006 Mar; 25(3):142-51. PubMed ID: 16569193
[TBL] [Abstract][Full Text] [Related]
25. Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity.
Speiser DE; Romero P
Semin Immunol; 2010 Jun; 22(3):144-54. PubMed ID: 20413326
[TBL] [Abstract][Full Text] [Related]
26. Clinical Experience and Recent Advances in the Development of
Oladejo M; Paterson Y; Wood LM
Front Immunol; 2021; 12():642316. PubMed ID: 33936058
[TBL] [Abstract][Full Text] [Related]
27. Oral vaccination with recombinant Listeria monocytogenes expressing human papillomavirus type 16 E7 can cause tumor growth in mice to regress.
Lin CW; Lee JY; Tsao YP; Shen CP; Lai HC; Chen SL
Int J Cancer; 2002 Dec; 102(6):629-37. PubMed ID: 12448006
[TBL] [Abstract][Full Text] [Related]
28. Cellular Mucins: Targets for Immunotherapy.
Apostolopoulos V; McKenzie IFC
Crit Rev Immunol; 2017; 37(2-6):421-437. PubMed ID: 29773028
[TBL] [Abstract][Full Text] [Related]
29. The tumor recall response of antitumor immunity primed by a live, recombinant Listeria monocytogenes vaccine comprises multiple effector mechanisms.
Weiskirch LM; Pan ZK; Paterson Y
Clin Immunol; 2001 Mar; 98(3):346-57. PubMed ID: 11237558
[TBL] [Abstract][Full Text] [Related]
30. Live-attenuated bacteria as a cancer vaccine vector.
Toussaint B; Chauchet X; Wang Y; Polack B; Le Gouëllec A
Expert Rev Vaccines; 2013 Oct; 12(10):1139-54. PubMed ID: 24124876
[TBL] [Abstract][Full Text] [Related]
31. Cancer immunotherapy using Listeria monocytogenes and listerial virulence factors.
Wood LM; Guirnalda PD; Seavey MM; Paterson Y
Immunol Res; 2008; 42(1-3):233-45. PubMed ID: 19018479
[TBL] [Abstract][Full Text] [Related]
32. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy.
Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K
Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391
[TBL] [Abstract][Full Text] [Related]
33. Central nervous system tumor immunity generated by a recombinant listeria monocytogenes vaccine targeting tyrosinase related protein-2 and real-time imaging of intracranial tumor burden.
Prins RM; Bruhn KW; Craft N; Lin JW; Kim CH; Odesa SK; Miller JF; Liau LM
Neurosurgery; 2006 Jan; 58(1):169-78; discussion 169-78. PubMed ID: 16385341
[TBL] [Abstract][Full Text] [Related]
34. Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccines.
Sinnathamby G; Lauer P; Zerfass J; Hanson B; Karabudak A; Krakover J; Secord AA; Clay TM; Morse MA; Dubensky TW; Brockstedt DG; Philip R; Giedlin M
J Immunother; 2009 Oct; 32(8):856-69. PubMed ID: 19752748
[TBL] [Abstract][Full Text] [Related]
35. Prophylactic and therapeutic efficacy of an attenuated Listeria monocytogenes-based vaccine delivering HPV16 E7 in a mouse model.
Jia Y; Yin Y; Duan F; Fu H; Hu M; Gao Y; Pan Z; Jiao X
Int J Mol Med; 2012 Dec; 30(6):1335-42. PubMed ID: 23027427
[TBL] [Abstract][Full Text] [Related]
36. A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours.
Pan ZK; Ikonomidis G; Lazenby A; Pardoll D; Paterson Y
Nat Med; 1995 May; 1(5):471-7. PubMed ID: 7585097
[TBL] [Abstract][Full Text] [Related]
37. The defined attenuated Listeria monocytogenes delta mp12 mutant is an effective oral vaccine carrier to trigger a long-lasting immune response against a mouse fibrosarcoma.
Paglia P; Arioli I; Frahm N; Chakraborty T; Colombo MP; Guzmàn CA
Eur J Immunol; 1997 Jun; 27(6):1570-5. PubMed ID: 9209512
[TBL] [Abstract][Full Text] [Related]
38. Listeria-based cancer vaccines that segregate immunogenicity from toxicity.
Brockstedt DG; Giedlin MA; Leong ML; Bahjat KS; Gao Y; Luckett W; Liu W; Cook DN; Portnoy DA; Dubensky TW
Proc Natl Acad Sci U S A; 2004 Sep; 101(38):13832-7. PubMed ID: 15365184
[TBL] [Abstract][Full Text] [Related]
39. A Genetically Modified attenuated
Jia YY; Tan WJ; Duan FF; Pan ZM; Chen X; Yin YL; Jiao XA
Front Cell Infect Microbiol; 2017; 7():279. PubMed ID: 28706878
[TBL] [Abstract][Full Text] [Related]
40. Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development.
Aguilar LK; Guzik BW; Aguilar-Cordova E
J Cell Biochem; 2011 Aug; 112(8):1969-77. PubMed ID: 21465529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
